Legal, supervised psilocybin therapy is available in only a handful of places worldwide. Australia is the only country with a national medical prescribing framework, while Oregon and Colorado have created state-level programs in the United States. A few other countries allow access through special permits or legal loopholes, but fully regulated therapeutic use remains rare.
Australia: The Only National Medical Framework
In July 2023, Australia became the first country to formally regulate psilocybin as a prescription medicine for a specific psychiatric condition. The Therapeutic Goods Administration (TGA) allows authorized psychiatrists to prescribe psilocybin for treatment-resistant depression, meaning depression that hasn’t responded to standard treatments. A separate authorization covers MDMA for PTSD, but psilocybin prescribing is limited to depression that has already failed conventional approaches.
Not every psychiatrist can prescribe it. Doctors must apply for individual authorization through the TGA, and the Royal Australian and New Zealand College of Psychiatrists has established a steering group to provide clinical guidance. In practice, access has been slow to scale. The number of authorized prescribers remains small, sessions are expensive, and most Australians with treatment-resistant depression still can’t easily access the therapy. But the legal pathway exists, which puts Australia ahead of every other nation in terms of formal medical regulation.
Oregon: First U.S. State With Licensed Services
Oregon legalized supervised psilocybin services through Measure 109 in 2020 and began licensing service centers in 2023. This is not a medical prescription model like Australia’s. You don’t need a diagnosis or a doctor’s referral. Adults 21 and older can visit a licensed service center, complete a preparation session, consume psilocybin under the supervision of a licensed facilitator, and then go through an integration session afterward.
The facilitator’s role is to provide support through a non-directive approach, meaning they don’t guide the experience toward specific therapeutic goals the way a therapist might. Each licensed service center sets its own pricing and procedures, and the Oregon Health Authority oversees licensing for both facilitators and centers. There’s no residency requirement, so people from other states can travel to Oregon for a session. Costs typically run between $1,000 and $3,500 per session depending on the center, though prices vary widely.
Colorado: A Newer Program Taking Shape
Colorado voters passed Proposition 122 in November 2022, creating the Natural Medicine Health Act. The state appointed a Natural Medicine Advisory Board in 2023 to develop regulations, and facilitator licensing opened in December 2024. The program is still in its early stages, with licensed healing centers expected to follow as the regulatory framework fills in.
Colorado’s model will look somewhat similar to Oregon’s: supervised sessions at licensed locations with trained facilitators. The law also includes provisions for personal use and “natural medicine” beyond psilocybin, covering several other plant-based psychedelics. But the supervised service center model is the piece most relevant to anyone looking for a structured therapeutic experience.
Canada: Case-by-Case Special Access
Canada doesn’t have a broad legal framework for psilocybin therapy, but it does offer a narrow pathway. Health Canada’s Special Access Program (SAP) allows healthcare practitioners to request access to otherwise unavailable drugs for patients with serious or life-threatening conditions when conventional treatments have failed, are unsuitable, or aren’t available in Canada.
This means a Canadian doctor with prescribing privileges can apply to use psilocybin for a specific patient, but they must demonstrate that standard options have been exhausted. The practitioner also has to ensure the patient understands the risks, report outcomes back to Health Canada, and keep detailed records. It’s a case-by-case authorization, not an open prescribing system, so access depends heavily on finding a willing and qualified provider who navigates the application process.
Switzerland: Limited Medical Use Permits
Switzerland has allowed restricted therapeutic use of psilocybin since 2021 through a provision in its narcotics law. The Swiss Federal Office of Public Health can issue authorizations for the limited medical use of otherwise prohibited substances on a case-by-case basis. This isn’t a broad clinical program. Individual practitioners apply for permission to use psilocybin with specific patients, similar in spirit to Canada’s approach but operating under different legal mechanisms.
Switzerland has a longer history with psychedelic-assisted therapy than most countries, and a small number of therapists have used these permits to treat patients. The program remains limited in scale, and access depends on finding a practitioner who has obtained the necessary authorization.
Countries Where Psilocybin Is Legal but Unregulated
A few places allow psilocybin possession and use without any formal therapeutic framework. In the Bahamas and the British Virgin Islands, psilocybin is legal to possess and use but not to sell. This has led to the growth of retreat centers, particularly in the Bahamas, that offer guided psilocybin experiences. These retreats operate in a legal gray area: the substance itself is legal, but there’s no government oversight of how sessions are conducted, who facilitates them, or what qualifications are required.
The Netherlands occupies a unique legal space. Psilocybin mushrooms are illegal, but psilocybin truffles (a different growth form of the same organism containing the same active compound) are legal. This has created a thriving retreat industry, particularly around Amsterdam, where facilitators offer guided truffle sessions. Again, this isn’t a regulated medical program. The quality of the experience depends entirely on the retreat operator.
Decriminalization Is Not Legalization
Several U.S. cities have decriminalized psilocybin possession, including Denver, Oakland, Ann Arbor, and Cambridge. The Czech Republic has similarly decriminalized personal possession of small amounts. Decriminalization means law enforcement treats possession as a low priority or imposes no criminal penalties, but it does not create any legal framework for therapeutic use. You can’t walk into a clinic in Denver and receive supervised psilocybin therapy just because the city has deprioritized enforcement.
This distinction matters because many people searching for legal psilocybin therapy encounter lists of decriminalized cities and assume those are places where they can access treatment. They’re not. Decriminalization reduces the personal legal risk of possessing small amounts, but it doesn’t license facilitators, regulate dosing, or create any therapeutic infrastructure. For supervised, legally sanctioned therapy, the options remain limited to the specific programs and countries described above.
What Access Actually Looks Like
For most people, the most accessible legal option right now is Oregon’s program, which requires no diagnosis and no residency. Colorado’s program is newer and still building out its infrastructure. Australia’s medical model offers the most clinical rigor but is limited to treatment-resistant depression patients who can find an authorized psychiatrist. Canada and Switzerland provide narrow compassionate-use pathways for people with serious conditions who have exhausted other treatments.
The practical barriers are significant everywhere. Cost is the biggest one: sessions in Oregon often run over $1,000 out of pocket, and insurance doesn’t cover psilocybin services anywhere. In Australia, the cost of a full treatment course can reach several thousand dollars. Travel is another factor, since legal options are concentrated in a few specific locations. And in countries with case-by-case authorization systems like Canada and Switzerland, simply finding a practitioner willing to navigate the bureaucratic process can be a challenge in itself.